普萘洛尔治疗新疆地区婴幼儿血管瘤的临床疗效观察及不良反应的应对

口腔医学研究 ›› 2015, Vol. 31 ›› Issue (7): 708-711.

普萘洛尔治疗新疆地区婴幼儿血管瘤的临床疗效观察及不良反应的应对

凌彬,尹小朋,张静,刘慧,龚忠诚,林兆全^*

新疆医科大学第一附属医院颌面肿瘤外科,新疆医科大学口腔医学院,新疆维吾尔自治区口腔医学研究所新疆乌鲁木齐 830054

收稿日期:2014-12-22 出版日期:2015-07-28 发布日期:2015-07-28
通讯作者: 林兆全,E-mail:lzqxhj@163.com
作者简介:凌彬(1981~ ),男,汉族,硕士,主治医师,主要从事口腔颌面部血管瘤的基础与临床研究。
基金资助:
新疆维吾尔自治区自然科学基金面上项目(编号:2013211A080)

Efficacy of Haemangioma Treated by Propranolol and the Treatment’s Complications in Xinjiang Region

LING Bin, YING Xiao-peng, ZHANG Jing, et al

Oncology Department of Oral & Maxillofacial Surgery, The First Teaching Hospital of Xinjiang Medical University, Stomatology College of Xinjiang Medical University, Stomatology Research Institute of Xinjiang Province,Urumqi 830054

Received:2014-12-22 Online:2015-07-28 Published:2015-07-28

摘要/Abstract

摘要： 目的:探讨普洛尔治疗婴幼儿血管瘤的临床疗效及不良反应的应对方法。方法:选择2011年11月~2013年10月在新疆医科大学第一附属医院颌面肿瘤外科接受口服普萘洛尔治疗婴幼儿血管瘤的50例患儿,年龄1~18个月,服药剂量:2 mg·kg^-1·d^-1。连续服用12个月,服药后定期复诊,动态评估患儿血管瘤体大小、质地、颜色、及不良反应。采用Achauer疗效评定法及彩色多普勒B超对临床疗效进行评估。定期复查其血糖、血压、肝肾功能等并对发生的不良反应积极应对。结果:50例患者治疗后12个月后Ⅰ级(差)4例; Ⅱ级(中)17例 ;Ⅲ级(好)18例;Ⅳ级(优)11例。不同性别、民族、瘤体部位与治疗效果之间无统计学差异;不同血管瘤分型(浅表型、混合型、深部型)与治疗效果之间有统计学差异(P<0.05)。16例患者治疗后出现不同类型并发症。结论:普萘洛尔治疗婴幼儿血管瘤安全有效且未见严重不良反应,出现相应的不良反应,应及时处理或暂时停药,其可作为治疗婴幼儿血管瘤临床一线治疗方案。

关键词: 婴幼儿血管瘤, 普萘洛尔, 疗效, 不良反应

Abstract: Objective:To evaluate the efficacy and respond to adverse reaction of propranolol in the treatment of infantile hemangiomas. Methods:A total of 50 infantile hemangiomas patients aged 1-18m were treated with propranolol at the dosage of 2mg/kg/d. The changes of tumor size, texture and color were monitored and recorded at a regular interval. The adverse effects after medication were observed. The short-term results were evaluated using a Achauer point scale system and color doppler ultrasound B. The adverse effects after medication therapy were observed and managed accordingly. Results:All 50 patients were followed up for 12months, the response was excellent in 11 patients, good in 18, moderate in 17, and poor in 4. There was no statistically significant between sex, race, tumor location and treatment efficacy. There was significantly different between the various type of hemangiomas(P<0.05).There were 16 patients who present various complications after treatment. Conclusion: Propranolol can be safely and effectively used to treat infantile hemangiomas. And no major side-effects were observed. This treatment should be considered as a promising alternative.

Key words: Infantile hemangioma, Propranolol, Efficacy, Side effect

中图分类号:

R739.8

凌彬,尹小朋,张静,刘慧,龚忠诚,林兆全. 普萘洛尔治疗新疆地区婴幼儿血管瘤的临床疗效观察及不良反应的应对[J]. 口腔医学研究, 2015, 31(7): 708-711.

LING Bin, YING Xiao-peng, ZHANG Jing, et al. Efficacy of Haemangioma Treated by Propranolol and the Treatment’s Complications in Xinjiang Region[J]. Journal of Oral Science Research, 2015, 31(7): 708-711.

参考文献

[1] Mulliken JB,Young AE. Vascular birthmarks:hemangiomas and malformations. Philadelphia, Saunders,1988∶412-413
[2] Léauté-Labréze C Prey S, Ezzedine K.Infantile haernangioma: Part I . Pathophysiology,epidemiology,clinical features,life cycle and associated structural abnormalities [J]. J Eur Acad Dermaml Venereol,2011,25(11)∶1245-1253
[3] Waner M, Suen JY. Hemangiomas and vascular malformations of the head and neck [M]. New York:Wiley-Liss inc, 1999, 3∶57-58, 93-169
[4] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy [J]. N Engl J Med, 2008,358(24):2649-2651. Buckmiller L,Dyamenahalli U,Richter GT.Propranolol for airway hemangiomas :case report of novel treatment [J]. Laryngoscope,2009,119∶2051-2054
[5] 龚忠诚,凌彬,克热木·阿巴司,等.普萘洛尔治疗24例婴幼儿血管瘤的临床观察[J].实用口腔医学杂志,2013,29(4)∶594-597
[6] Achauer BM, Chang CJ, Vander Kam VM. Management of haemangioma of infancy: review of 245 patients [J]. Plast Reconstr Surg, 1997, 99(5)∶1301-1308
[7] Lawley LP,Siegfried E,Todd JL.Propranolol treatment for hemangioma of infancy:risks and recommendations [J]. Pediatr Dermatol,2009,26(5)∶610-614
[8] Akhavan A, Zippin JH. Current treatment for infantile heamangiomas [J]. J Druga Dermatol,2010,9(2)∶176-180
[9] Maguiness SM, Friden IJ. Current management of infantlie heamangiomas [J]. Semin Cutan Med Surg,2010,29(2)∶106-114[10] Chen W, Li J, Yang Z, et al. SMAS fold flap and ADM repair of the parotid bed following removal of parotid heamangiomas viapre-and retroauricular incisions to improve cosmetic outcome and prevent Frey’s syndrome [J]. J Plast Reconstr Aesthet Surg,2008,61(8)∶894-899
[11] Chen WL, Zhang B, Li JS, et al. Liquid nitrogen cryotherapy of lip mucosa heamangiomas under inhalation general ansthesia with sevoflurance in early infancy [J]. Ann Plast Surg,2009,62(2)∶154-157
[12] Bauman NM, Burke DK, Smith RJ. Treatment of massive or life-threatening hemangiomas with recombinant alpha(2a)-interferon [J]. Otol aryngol Head Neck Snrg, 1997, 17(1)∶99-110
[13] Moshovi M, Alexiou GA, Stefanaki K, et al. Propranolol treatment for a giant infantile brain cavernoma [J]. J Child Neurol,2010,25(5)∶653-655
[14] Lawley L; Siegfried E. Propranolol treatment for hemangiomas of infancey:risks and recommendations [J]. Pediatr Dermatol,2009,26(5)∶610-614